Cargando…
A human monoclonal antibody blocking SARS-CoV-2 infection
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (a...
Autores principales: | Wang, Chunyan, Li, Wentao, Drabek, Dubravka, Okba, Nisreen M. A., van Haperen, Rien, Osterhaus, Albert D. M. E., van Kuppeveld, Frank J. M., Haagmans, Bart L., Grosveld, Frank, Bosch, Berend-Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198537/ https://www.ncbi.nlm.nih.gov/pubmed/32366817 http://dx.doi.org/10.1038/s41467-020-16256-y |
Ejemplares similares
-
Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
por: Wang, Chunyan, et al.
Publicado: (2020) -
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
por: Widjaja, Ivy, et al.
Publicado: (2019) -
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
por: Wang, Chunyan, et al.
Publicado: (2021) -
Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
por: Du, Wenjuan, et al.
Publicado: (2023) -
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
por: Du, Wenjuan, et al.
Publicado: (2022)